Dry and Wet Age-Related Macular Degeneration – Unmet Need – Unmet Need – Geographic Atrophy (US/EU)
Geographic atrophy (GA) is an advanced stage of age-related macular degeneration characterized by the progressive and irreversible degeneration of retinal tissue, including photoreceptors. This condition leads to a gradual loss of central vision, significantly affecting patients’ daily activities and independence. The introduction of the first therapies approved for GA, Apellis’s Syfovre (pegcetacoplan) and Astellas’s Izervay (avacincaptad pegol), in the United States in 2023 revolutionized the treatment landscape. These intravitreal complement system inhibitors offer new therapeutic options beyond traditional over-the-counter vitamin supplements (i.e., AREDS 1 and AREDS 2). However, they face intensifying competition as numerous companies advance GA therapies in their pipelines and explore novel mechanisms of action. Understanding the factors that influence physicians’ choice of therapy for GA and identifying the key areas of unmet need in the treatment of this disease will be crucial to the strategic positioning of novel agents in this rapidly evolving market.
Questions answered
- What are the most important factors driving ophthalmologists’ prescribing decisions for GA? Do these factors differ between U.S. and European ophthalmologists?
- How do U.S. ophthalmologists perceive Syfovre and Izervay performing on key clinical attributes for GA? How different is their clinical performance compared with that of the AREDS supplements, according to ophthalmologists?
- What are the prevailing areas of unmet need in GA?
- What trade-offs are surveyed ophthalmologists willing to make across key clinical attributes and price for a new GA therapy?
Geography: United States, France, Germany, United Kingdom
Primary research: Survey of 61 U.S. and 30 European ophthalmologists
Key drugs covered: Syfovre, Izervay
Product description
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Key feature: The Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
